BOOK
Biosimilars and Biologics: Implementation and Monitoring in a Health Care Setting
Implementation and Monitoring in a Health Care Setting
(2018)
Additional Information
Book Details
Abstract
Get Up to Speed on the Fastest Growing Pharmaceutical Innovation with the Only Guide Written for Pharmacists
Among the most anticipated and discussed segments of the pharmaceutical market, biosimilars are finally beginning to exert a greater impact on practice. To meet the growing need for information, ASHP has published Biosimilars & Biologics: Implementation and Monitoring in a Healthcare Setting.
Steven Lucio, PharmD, BCPS is Associate Vice President at Vizient, Inc. and formerly served as its Associate Vice President. Prior to joining Vizient, Lucio practiced for almost 10 years within the Baylor Health Care System in various settings, including ICU clinical pharmacy and geriatric ambulatory care. Dr. Lucio earned his Doctor of Pharmacy degree from Creighton University and a Bachelor of Science degree in Pharmacy from the University of Texas at Austin. He is a Board Certified Pharmacotherapy Specialist.Among the most anticipated and discussed segments of the pharmaceutical market, biosimilars are finally beginning to exert a greater impact on practice. To meet the growing need for information, ASHP has published Biosimilars & Biologics: Implementation and Monitoring in a Healthcare Setting.
Lucio is lead author of a recently published peer-reviewed article on biosimilars. He is an active speaker and panel moderator and has presented his insight on biosimilars more than a dozen times in the past year.
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Dedication | 3 | ||
| Table of Contents | 5 | ||
| Preface | 7 | ||
| Chapter 1: A New Type of Blockbuster: The Growth of Biologics | 11 | ||
| Chapter 2: Déjà Vu or Something New?—Comparing the Generic and Biosimilar Experiences | 21 | ||
| Chapter 3: Bugs and Drugs, and Yeast and Mice, and Chinese Hamsters | 31 | ||
| Chapter 4: The $250 Billion Pyramid: Analytics in Biosimilarity Determination | 43 | ||
| Chapter 5: The Global Biosimilars Experience | 67 | ||
| Chapter 6: The American Biosimilar Experience: Red, White, and Possibly Interchangeable | 81 | ||
| Chapter 7: Biosimilar Clinical Trial Requirements | 101 | ||
| Chapter 8: Immunogenicity and Pharmacovigilance in the Biosimilar Era | 123 | ||
| Chapter 9: The Patent Dance and the Exclusivity Shuffle | 137 | ||
| Chapter 10: Defining Biosimilar Value and Other Seemingly Impossible Tasks | 149 | ||
| Chapter 11: Biosimilar Formulary Management Strategies | 163 | ||
| Conclusion: Biosimilars 2023 | 177 | ||
| Index | 181 |